CN102395377B - 增强肌肉功能的肽 - Google Patents

增强肌肉功能的肽 Download PDF

Info

Publication number
CN102395377B
CN102395377B CN201080016920.2A CN201080016920A CN102395377B CN 102395377 B CN102395377 B CN 102395377B CN 201080016920 A CN201080016920 A CN 201080016920A CN 102395377 B CN102395377 B CN 102395377B
Authority
CN
China
Prior art keywords
seq
calcium
peptide
amino acid
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080016920.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102395377A (zh
Inventor
P·莫斯特
M·福尔克斯
H·卡图斯
A·雷姆皮斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Heidelberg
Original Assignee
Heidelberg university hospital
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg university hospital, Universitaet Heidelberg filed Critical Heidelberg university hospital
Publication of CN102395377A publication Critical patent/CN102395377A/zh
Application granted granted Critical
Publication of CN102395377B publication Critical patent/CN102395377B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201080016920.2A 2009-04-16 2010-04-16 增强肌肉功能的肽 Expired - Fee Related CN102395377B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16996209P 2009-04-16 2009-04-16
US61/169962 2009-04-16
PCT/EP2010/002343 WO2010118878A1 (en) 2009-04-16 2010-04-16 Muscle function enhancing peptide

Publications (2)

Publication Number Publication Date
CN102395377A CN102395377A (zh) 2012-03-28
CN102395377B true CN102395377B (zh) 2016-10-19

Family

ID=42226606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080016920.2A Expired - Fee Related CN102395377B (zh) 2009-04-16 2010-04-16 增强肌肉功能的肽

Country Status (7)

Country Link
US (1) US9428564B2 (https=)
EP (1) EP2419119B1 (https=)
JP (1) JP5847073B2 (https=)
CN (1) CN102395377B (https=)
CA (1) CA2756249C (https=)
ES (1) ES2638043T3 (https=)
WO (1) WO2010118878A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052177A1 (en) * 2010-10-20 2012-04-26 Universität Heidelberg Short peptides for enhancing muscle function
CA2925691A1 (en) 2013-10-01 2015-04-09 Ruprecht-Karls-Univeristat Heidelberg S100 based treatment of cardiac power failure
CN117589740B (zh) * 2024-01-04 2025-02-11 南京市产品质量监督检验院(南京市质量发展与先进技术应用研究院) 一种高通量快速检测和评估化合物骨骼肌毒性的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061742A2 (de) * 1999-04-07 2000-10-19 Katus Hugo A Therapie der herzinsuffizienz durch verwendung der s100-proteinen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553929B2 (en) * 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061742A2 (de) * 1999-04-07 2000-10-19 Katus Hugo A Therapie der herzinsuffizienz durch verwendung der s100-proteinen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Molecular Characterization and Tissue Distribution of a Novel Member of the S100 Family of EF-Hand Proteins";Alexey V. et. al.;<Biochemistry>;20011231;第40卷(第51期);第15538-15548页 *

Also Published As

Publication number Publication date
EP2419119B1 (en) 2017-06-07
EP2419119A1 (en) 2012-02-22
CA2756249C (en) 2020-08-18
CA2756249A1 (en) 2010-10-21
WO2010118878A1 (en) 2010-10-21
US20120129758A1 (en) 2012-05-24
ES2638043T3 (es) 2017-10-18
JP5847073B2 (ja) 2016-01-20
CN102395377A (zh) 2012-03-28
US9428564B2 (en) 2016-08-30
JP2012524034A (ja) 2012-10-11

Similar Documents

Publication Publication Date Title
US20170119853A1 (en) Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
US12351609B2 (en) Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
US8685928B2 (en) Antagonists of MUC1
JP2017197581A (ja) バイグリカン変異体および関連する治療薬および使用方法
CN102395377B (zh) 增强肌肉功能的肽
US10653749B2 (en) Targeting GIV-GEF-GI signaling for treating diverse diseases
US9453053B2 (en) Short peptides for enhancing muscle function
US20060211606A1 (en) Peptides
AU2013329296B2 (en) Biglycan variant polypeptides and methods of use
US20140303093A1 (en) Micro-utrophin polypeptides and methods
HK1167331A (en) Muscle function enhancing peptide
HK1167331B (en) Muscle function enhancing peptide
JP7486285B2 (ja) 対象における拡張機能障害を治療するための手段及び方法
CA2601227A1 (en) Mecano growth factor peptides and their use
WO2019051111A1 (en) Purified biglycan variants and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: RUPRECHT-KARLS UNIVERSITY HEIDELBERG

Free format text: FORMER OWNER: HEIDELBERG UNIVERSITY HOSPITAL

Effective date: 20140312

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140312

Address after: Heidelberg

Applicant after: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG

Address before: Heidelberg

Applicant before: Heidelberg University Hospital

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161019